<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Hemopoietic cell transplantation (HCT) is presently the only therapy with curative potential for <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) and <z:hpo ids='HP_0005547'>myeloproliferative disorders</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MPD</z:e>) </plain></SENT>
<SENT sid="1" pm="."><plain>Among patients with less advanced <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>, 3-year survival figures of 65-80% are achieved with human leukocyte antigen (HLA)-identical related and unrelated donors </plain></SENT>
<SENT sid="2" pm="."><plain>The probability of relapse is less than 5% </plain></SENT>
<SENT sid="3" pm="."><plain>Among patients with advanced <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> (&gt; or = 5% marrow blasts), about 35-50% of patients transplanted from related donors, and 25-40% transplanted from unrelated donors are surviving in remission beyond 3 years </plain></SENT>
<SENT sid="4" pm="."><plain>The incidence of post-transplant relapse is 10-35% </plain></SENT>
<SENT sid="5" pm="."><plain>Criteria of the International Prognostic Scoring System (IPSS) predict relapse and survival following HCT </plain></SENT>
<SENT sid="6" pm="."><plain>In patients with <z:hpo ids='HP_0011974'>myelofibrosis</z:hpo>, allogeneic transplantation is successful in 50-80%, if performed during the <z:mp ids='MP_0003045'>fibrosis</z:mp> stage </plain></SENT>
<SENT sid="7" pm="."><plain>The success rate declines to 25-40%, if the transplant is performed after leukemic transformation has occurred </plain></SENT>
<SENT sid="8" pm="."><plain>About 40% of patients with <z:hpo ids='HP_0011010'>chronic</z:hpo> myelomonocytic <z:hpo ids='HP_0001909'>leukemia</z:hpo> survive in remission after transplantation </plain></SENT>
<SENT sid="9" pm="."><plain>Results obtained with low/reduced-intensity conditioning regimens are encouraging because of a low incidence of early mortality </plain></SENT>
<SENT sid="10" pm="."><plain>However, retrospective analyses comparing low intensity and conventional conditioning regimens have yielded inconclusive results regarding long-term outcome </plain></SENT>
<SENT sid="11" pm="."><plain>Co-morbid conditions present at the time of transplantation have a major negative effect on transplant outcome </plain></SENT>
<SENT sid="12" pm="."><plain>Controlled prospective trials are needed </plain></SENT>
</text></document>